Jean Pierre Bizzari - Jun 5, 2025 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/9/2025, 04:01 PM
Previous filing
Jun 5, 2025
Next filing
Jun 17, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BIZZARI JEAN-PIERRE Director 3805 OLD EASTON ROAD, DOYLESTOWN /s/ John Hamill, as Attorney-in-Fact 2025-06-09 0001630914

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +1.05K $0.00 1.05K Jun 5, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +4.19K $0.00 4.19K Jun 5, 2025 Common Stock 4.19K $1.81 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.
F2 The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions.